Circulating levels of inflammatory cytokines interleukin 6 (IL-6) and monocyte chemoattractant protein 1 (MCP1) trended lower in all treatment groups compared to control, although differences did not reach statistical significance ( Figure 4 E,F).
← all excerpts
Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
1
—
—